Abstract:Introduction: Accumulating data has demonstrated the crucial role of immunity in TNBC biology, suggesting the potential involvement of immunotherapy to treat this malignancy. A variety of different immuno[[Unsupported Character - Codename ]]therapeutic strategies, such as anti-PD-1 or anti-PD-L1, are currently being tested in preclinical studies in TNBC patients. However, the response rate (RR) to PD-1 or PD-L1 antibody remains low in TNBC. Autophagy regulates the antitumor immune response. The mechanism that autopahgy stimulates or limits the T cell immune system’s attack on tumor cells has not been well understood. Here, we examine the complex role of autophagy in TNBC tumor immunity.Methods: We depleted Atg5, Atg7 and Beclin1 expression using specific single-guide RNAs (sgRNAs) to construct autophagy-deficient TNBC cell lines. The caspase-3 cleavage assay and lactat dehydrogenase-release (LDH) assay were performed to measuring T-cell-mediated cytotoxicity. SILAC and high-resolution MS procedures were implemented to quantify protein variations between autophagy-competent and autophagy- incompetent cells. Flow cytometry analysis was performed to detect the proliferation and activity of T cells. IHC was performed with antibody against Tenascin-C (TNC), LC3, CD8 in paraffin blocks of human TNBC breast lesions. The blockade of TNC alone or in combination with immunotherapy was determined. Statistical analyses were conducted using GraphPad Prism, SPSS software and JavaGSEA Desktop Application. A p value of <0.05 was considered to indicate statistical significance.Results: We found that only in basal tumors but not in Luminal and Her2 tumors, Atg5 and Beclin 1 expression were found to be positively related with the abundance of B cells, CD4 T cells, CD8 T cells, neutrophils, and dendritic cells. The failure of autophagy contributed to the limitation of T-lymphocytes immune system’s attack on TNBC cells in vitro and in vivo. We also identified a novel role for TNC as a key regulator of autophagy-deficient-mediated immunosuppression, in which TNC was Lys63 ubiquitinated by the E3 ligase SKP2, thus promoting its recognition by the autophagy receptorp62 and leading to its selective degradation. The degradation of TNC by the autophagy-lysosome pathway was physiologically significant and clinically relevant in TNBC patients. More importantly, we demonstrated that blockade of TNC sensitized T cell-mediated tumor killing and improved the antitumor effects by PD1 blockade in autophagy-impaired TNBC tumors.Conclusion: Our studies identify a crosstalk between autophagy and immune compartments as a novel therapeutic strategy for TNBC patients with poor immunotherapy response. Our findings indicates that blockade of TNC may be an effective adjuvant treatment with immunotherapy as a novel management strategy for TNBC patients, especially with autophagy deficiency.Note: This abstract was not presented at the meeting.Citation Format: Rong Deng, Zhi-ling Li, Hai-Liang Zhang, Xuan Li, Jia Mia, Li-Huan Zhou, Yun Huang, Yan Yu, Jun Tang, Xiao-Feng Zhu. Abnormality of selective autophagic degradation of tenascin-C promotes resistance to T cell-mediated immune attack in triple negative breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 4950.

Abstract 4317: The role of autophagy in triple negative breast cancer

Novel combinatorial autophagy inhibition therapy for triple negative breast cancers

The Cytoprotective Role Of Gemcitabine-Induced Autophagy Associated With Apoptosis Inhibition In Triple-Negative Mda-Mb-231 Breast Cancer Cells

Abstract 4950: Abnormality of Selective Autophagic Degradation of Tenascin-C Promotes Resistance to T Cell-Mediated Immune Attack in Triple Negative Breast Cancer

Abstract 3545: Autophagy Inhibition As a Therapeutic Strategy in Cancer

Abstract 7151: Targeting metabolic pathway in triple negative breast cancer with a small molecule inhibitor

Abstract LB-107: Targeting the Glycolytic Pathway As an Effective Therapeutic Approach for Triple-Negative Breast Cancer

Abstract B53: The role of RPL39 induced autophagy in resistance of breast cancer stem cells

Abstract 2865: Dual action glycotherapy for triple negative breast cancer

Abstract 3076: Unveiling the therapeutic potential of β-catenin inhibition in triple negative breast cancers: Targeting the Warburg effect

Abstract 2328: Macrophage-targeting immunotherapy for triple negative breast cancer

Abstract 5791: Autophagy & PIM1 Kinase Inhibition in Breast Cancer Stem Cells & Bulk Cancer Cells Attenuates Breast Cancer & Metastasis

Dual Action Glycotherapy For Triple Negative Breast Cancer

Exploring the Potential of Nanomolecular Therapeutic Therapy Options, and Novel Biomarkers in Triple-negative Breast Cancer Treatment

Abstract 3074: Regulating lactate levels in triple negative breast cancer presents a promising avenue for therapeutic intervention

Abstract 573: SLC22A17 as a promising target for triple-negative breast cancer

Abstract 4692: A novel ceramide synthase 2 agonist and its implication in triple-negative breast cancer therapy

Abstract 6521: Macrophage-targeting immunotherapy enhances chemotherapy response in primary and metastatic triple-negative breast cancer models

Abstract 4610: Dual inhibition of CDK4/6 and IL-6 pathways as a novel therapeutic approach for triple-negative breast cancer cells

Autocrine Motility Factor and Its Peptide Derivative Inhibit Triple-Negative Breast Cancer by Regulating Wound Repair, Survival, and Drug Efflux

Novel Ways of Targeting Triple Negative Breast Cancer (TNBC) with the Latest Research - will it Improve Prognoses